Neurocrine Biosciences Inc at Goldman Sachs Global Healthcare Conference Transcript
Good morning, and welcome, everybody. The Wednesday, the Goldman Sachs Healthcare Conference. My name is Chris Shibutani. I'm a member of the research team, together with my esteemed colleague, Stephen Sloan. We provide coverage on Neurocrine. We're part of the biotech and pharmaceuticals team. We're thrilled to have an in-person gathering after all of this time with the team from Neurocrine, Kevin Gorman, CEO; and the ridiculously tall Matt Abernethy, CFO.
I was born this way.
Yes, indeed. If anybody have seen the infamous Todd Tushla, he's got a great haircut going. So it's great to see everybody in-person, live and in action.
Obvious thematic around your story is the innovation, the pioneering on INGREZZA, right? TD, the journey that this drug has been on, and I go back to a bunch of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
